Standard BioTools
LAB
135 hedge funds and large institutions have $864M invested in Standard BioTools in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 23 closing their positions.
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
26% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 43
8.48% more ownership
Funds ownership: 93.19% → 101.67% (+8.5%)
3% more funds holding
Funds holding: 131 → 135 (+4)
1% more capital invested
Capital invested by funds: $854M → $864M (+$10.1M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
97% less call options, than puts
Call options by funds: $6K | Put options by funds: $196K
Top Buyers
| 1 |
BlackRock
New York
|
+$29.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.8M |
| 3 |
Morgan Stanley
New York
|
+$19M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$14.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.18M |
Top Sellers
LAB Hedge Fund Activity: Q2 2019 in Review
135 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2019, worth a combined $864M — up 1.2% from $854M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LAB positions and 23 closed out — a net gain of 6 holders — while 54 added to existing stakes and 43 trimmed.
The largest buyer was BlackRock, adding an estimated $29.2M. The largest seller was Easterly Investment Partners, cutting an estimated $18.2M.
- 135 institutional investors held Standard BioTools (LAB) as of Q2 2019, up from 131 in Q1 2019.
- Funds reported $864M of Standard BioTools stock for Q2 2019, up 1.2% quarter-over-quarter.
- 29 funds opened new Standard BioTools positions in Q2 2019 and 23 closed out, a net change of +6 holders.
- The largest Standard BioTools buyer in Q2 2019 was BlackRock, an estimated $29.2M added.
- The largest Standard BioTools seller in Q2 2019 was Easterly Investment Partners, an estimated $18.2M sold.
Based on aggregated 13F filings for Q2 2019.